New Insights Into Pharmacology of GABAA Receptor Alpha Subunits-Selective Modulators.
Journal
American journal of therapeutics
ISSN: 1536-3686
Titre abrégé: Am J Ther
Pays: United States
ID NLM: 9441347
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Benzodiazepines have long held a leading position in medical therapeutics, known for their multiple common therapeutic properties and primarily being prescribed for anxiety and insomnia. However, their lack of specificity and various side effects have led to a reevaluation of their long-term use, resulting in a rapid growth in the literature focusing on targeted therapies. Despite many efforts, uncertainties persist and there are heterogeneous findings across studies regarding the pharmacological effects attributed to gamma-aminobutyric acid type A (GABAA) receptor subunits. Selective compounds targeting GABAA receptor alpha subunits are currently under active research and definitive conclusions have not been reached yet. Some compounds have not progressed to clinical trials, while others, if advanced, have been halted. These challenges emphasize the difficulty in translating preclinical findings into clinical use. A literature review was conducted using the PubMed database, searching for articles discussing GABAA receptor subunits. The search was refined by including only selective compounds with potential anxiolytic and cognitive enhancement properties. Findings reveal compounds with promising anxiolytic and antidepressant effects with minimal sedation and absence of tolerance development. Moreover, some compounds show potential in alleviating cognitive dysfunction. There is a broad spectrum of potential therapeutic applications for selective compounds, ranging from neurological disorders such as epilepsy and neuropathic pain to cognitive dysfunction-related conditions. Currently, the leading selective compounds with the most promising results in ongoing clinical trials are basmisanil and darigabat. Basmisanil holds further exploration potential in the treatment of cognitive impairment and related conditions, while darigabat shows progress in the advancement of adjunctive therapy of focal onset seizures and for the treatment of panic disorder, respectively. Future drug discovery efforts are encouraged to focus on positive allosteric modulators that selectively target the α2, α3 subunits and negative/positive allosteric modulators that target the α5 subunit of the GABAA receptor. The pursuit of ligands possessing only anxiolytic effects or those enhancing cognition continues to be an important focus for future research, with promising advancements depicted in recent studies.
Sections du résumé
BACKGROUND
BACKGROUND
Benzodiazepines have long held a leading position in medical therapeutics, known for their multiple common therapeutic properties and primarily being prescribed for anxiety and insomnia. However, their lack of specificity and various side effects have led to a reevaluation of their long-term use, resulting in a rapid growth in the literature focusing on targeted therapies.
AREAS OF UNCERTAINTY
UNASSIGNED
Despite many efforts, uncertainties persist and there are heterogeneous findings across studies regarding the pharmacological effects attributed to gamma-aminobutyric acid type A (GABAA) receptor subunits. Selective compounds targeting GABAA receptor alpha subunits are currently under active research and definitive conclusions have not been reached yet. Some compounds have not progressed to clinical trials, while others, if advanced, have been halted. These challenges emphasize the difficulty in translating preclinical findings into clinical use.
DATA SOURCES
METHODS
A literature review was conducted using the PubMed database, searching for articles discussing GABAA receptor subunits. The search was refined by including only selective compounds with potential anxiolytic and cognitive enhancement properties.
RESULTS
RESULTS
Findings reveal compounds with promising anxiolytic and antidepressant effects with minimal sedation and absence of tolerance development. Moreover, some compounds show potential in alleviating cognitive dysfunction. There is a broad spectrum of potential therapeutic applications for selective compounds, ranging from neurological disorders such as epilepsy and neuropathic pain to cognitive dysfunction-related conditions. Currently, the leading selective compounds with the most promising results in ongoing clinical trials are basmisanil and darigabat. Basmisanil holds further exploration potential in the treatment of cognitive impairment and related conditions, while darigabat shows progress in the advancement of adjunctive therapy of focal onset seizures and for the treatment of panic disorder, respectively.
CONCLUSIONS
CONCLUSIONS
Future drug discovery efforts are encouraged to focus on positive allosteric modulators that selectively target the α2, α3 subunits and negative/positive allosteric modulators that target the α5 subunit of the GABAA receptor. The pursuit of ligands possessing only anxiolytic effects or those enhancing cognition continues to be an important focus for future research, with promising advancements depicted in recent studies.
Identifiants
pubmed: 39240716
doi: 10.1097/MJT.0000000000001810
pii: 00045391-990000000-00218
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Griffin CE, Kaye AM, Bueno FR, et al. Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner J. 2013;13:214–223.
Ator NA. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr. 2005;10:31–39.
Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 2005;10:49–56.
Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10:685–697.
Jembrek MJ, Vlainic J. GABA receptors: pharmacological potential and pitfalls. Curr Pharm Des. 2015;21:4943–4959.
Langer S, Arbilla S, Tan S, et al. Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry. 1990;23:103–107.
Ghit A, Assal D, Al-Shami AS, et al. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021;19:123.
Sieghart W, Savić MM. International Union of Basic and Clinical Pharmacology. CVI: GABAA receptor subtype- and function-selective ligands: key issues in translation to humans. Pharmacol Rev. 2018;70:836–878.
Engin E, Liu J, Rudolph U. α2-containing GABAA receptors: a target for the development of novel treatment strategies for CNS disorders. Pharmacol Ther. 2012;136:142–152.
Cheng T, Wallace DM, Ponteri B, et al. Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects. Neuropsychiatr Dis Treat. 2018;14:1351–1361.
Cutler AJ, Mattingly GW, Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry. 2023;13:1–16.
Jensen HS, Nichol K, Lee D, et al. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABAA–receptor complexes. PLoS ONE. 2014;9:e88456.
Hadingham KL, Wingrove P, Le Bourdelles B, et al. Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors. Mol Pharmacol. 1993;43:970–975.
Reynolds LM, Engin E, Tantillo G, et al. Differential roles of GABAA receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward. Neuropsychopharmacology. 2012;37:2531–2540.
Olsen RW, Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009;56:141–148.
Pritchett DB, Lüddens H, Seeburg PH. Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science. 1989;245:1389–1392.
Albaugh PA, Marshall L, Gregory J, et al. Synthesis and biological evaluation of 7,8,9,10-tetrahydroimidazo[1,2-c]pyrido[3,4-e]pyrimdin-5(6H)-ones as functionally selective ligands of the benzodiazepine receptor site on the GABA(A) receptor. J Med Chem. 2002;45:5043–5051.
Huang Q, He X, Ma C, et al. Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach. J Med Chem. 2000;43:71–95.
Harris D, Clayton T, Cook J, et al. Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the alpha5 subunit. J Med Chem. 2008;51:3788–3803.
Söderhielm PC, Balle T, Bak-Nyhus S, et al. Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors. Biochem Pharmacol. 2018;158:339–358.
Lewter LA, Fisher JL, Siemian JN, et al. Antinociceptive effects of a novel α2/α3-subtype selective GABAA receptor positive allosteric modulator. ACS Chem Neurosci. 2017;8:1305–1312.
Atack JR. GABAA receptor subtype‐selective efficacy: TPA023, an α2/α3 selective non‐sedating anxiolytic and α5IA, an α5 selective cognition enhancer. CNS Neurosci Ther. 2008;14:25–35.
Atack JR, Hallett DJ, Tye S, et al. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist. J Psychopharmacol. 2011;25:329–344.
Hipp JF, Knoflach F, Comley R, et al. Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. Sci Rep. 2021;11:7700.
Chambers MS, Atack JR, Carling RW, et al. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. J Med Chem. 2004;47:5829–5832.
Owen RM, Blakemore D, Cao L, et al. Design and Identification of a Novel, Functionally Subtype Selective GABAA Positive Allosteric Modulator (PF-06372865). J Med Chem. 2019;62:5773–5796.
Rudolph U, Möhler H. GABAA Receptor Subtypes. Annu Rev Pharmacol Toxicol. 2014;54:483–507.
McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3:587–592.
Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl). 1994;116:130–134.
Heikkinen AE, Möykkynen TP, Korpi ER. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacology. 2009;34:290–298.
Huskinson SL, Freeman KB, Rowlett JK. Self-administration of benzodiazepine and cocaine combinations by male and female rhesus monkeys in a choice procedure: role of α1 subunit-containing GABAA receptors. Psychopharmacology (Berl). 2019;236:3271–3279.
Crestani F, Löw K, Keist R, et al. Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol. 2001;59:442–445.
Meng Z, Berro LF, Sawyer EK, et al. Evaluation of the anti-conflict, reinforcing, and sedative effects of YT-III-31, a ligand functionally selective for α3 subunit-containing GABAA receptors. J Psychopharmacol. 2020;34:348–357.
Batinić B, Stanković T, Stephen MR, et al. Attaining in vivo selectivity of positive modulation of α3βγ2 GABAA receptors in rats: a hard task! Eur Neuropsychopharmacol. 2018;28:903–914.
Crestani F, Keist R, Fritschy JM, et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A. 2002;99:8980–8985.
Dawson GR, Maubach KA, Collinson N, et al. An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther. 2006;316:1335–1345.
Nickolls S, Mace H, Fish R, et al. A comparison of the α2/3/5 selective positive allosteric modulators L-838,417 and TPA023 in preclinical models of inflammatory and neuropathic pain. Adv Pharmacol Sci. 2011;2011:608912.
Tietz EI, Rosenberg HC, Chiu TH. Autoradiographic localization of benzodiazepine receptor downregulation. J Pharmacol Exp Ther. 1986;236:284–292.
Arnot MI, Davies M, Martin IL, et al. GABA(A) receptor gene expression in rat cortex: differential effects of two chronic diazepam treatment regimes. J Neurosci Res. 2001;64:617–625.
Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des. 2002;8:5–21.
Hernandez TD, Heninger C, Wilson MA, et al. Relationship of agonist efficacy to changes in GABA sensitivity and anticonvulsant tolerance following chronic benzodiazepine ligand exposure. Eur J Pharmacol. 1989;170:145–155.
Gonsalves SF, Gallager DW. Persistent reversal of tolerance to anticonvulsant effects and GABAergic subsensitivity by a single exposure to benzodiazepine antagonist during chronic benzodiazepine administration. J Pharmacol Exp Ther. 1988;244:79–83.
Gravielle MC. Activation-induced regulation of GABAA receptors: is there a link with the molecular basis of benzodiazepine tolerance? Pharmacol Res. 2016;109:92–100.
Auta J, Impagnatiello F, Kadriu B, et al. Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology. 2008;55:148–153.
Morales M, Varlinskaya EI, Spear LP. Anxiolytic effects of the GABAA receptor partial agonist, L-838,417: impact of age, test context familiarity, and stress. Pharmacol Biochem Behav. 2013;109:31–37.
Reeves-Darby JA, Berro LF, Platt DM, et al. Pharmaco-EEG analysis of ligands varying in selectivity for α1 subunit-containing GABAA receptors during the active phase in rats. Psychopharmacology. 2023;240:2561–2571.
Lorenzo LE, Godin AG, Ferrini F, et al. Enhancing neuronal chloride extrusion rescues α2/α3 GABAA-mediated analgesia in neuropathic pain. Nat Commun. 2020;11:869.
Sharmin D, Mian MY, Marcotte M, et al. Synthesis and receptor binding studies of α5 GABAAR selective novel imidazodiazepines targeted for psychiatric and cognitive disorders. Molecules. 2023;28:4771.
Fogaça MV, Duman RS. Cortical GABAergic dysfunction in stress and depression: new insights for therapeutic interventions. Front Cell Neurosci. 2019;13:87.
Perez SM, McCoy AM, Prevot TD, et al. Hippocampal α5-GABAA receptors modulate dopamine neuron activity in the rat ventral tegmental area. Biol Psychiatry Glob Open Sci. 2022;3:78–86.
Witkin JM, Lippa A, Smith JL, et al. The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. Pharmacol Biochem Behav. 2022;213:173321.
Nakakubo S, Hiramatsu Y, Goto T, et al. Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABAA receptors, in a mouse model of Dravet syndrome. Front Pharmacol. 2023;14:1273633.
Smith JL, Wertz J, Lippa A, et al. KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy. Heliyon. 2024;10:5.
Witkin JM, Smith JL, Ping X, et al. Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: improved bioavailability enhances anticonvulsant efficacy. Neuropharmacology. 2018;137:332–343.
de Haas SL, de Visser SJ, van der Post JP, et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol. 2007;21:374–383.
Atack JR. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci. 2010;2:331–360.
Neumann E, Küpfer L, Zeilhofer HU. The α2/α3GABAA receptor modulator TPA023B alleviates not only the sensory but also the tonic affective component of chronic pain in mice. Pain. 2021;162:421–431.
Hipp JF, Knoflach F, Comley R, et al. Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. Sci Rep. 2021;11:7700.
Ballard TM, Knoflach F, Prinssen E, et al. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl). 2009;202:207–223.
Hoffmann-La Roche. Information provided by Hoffmann-La Roche (Responsible Party). Available at: https://clinicaltrials.gov/study/NCT02953639. Accessed May 16, 2024.
Kwakowsky A, Waldvogel HJ, Faull RLM. Therapeutic potential of alpha 5 subunit containing GABAA receptors in Alzheimer's disease. Neural Regen Res. 2021;16:1550–1551.
Paunescu H, Dima L, Ghita I, et al. A systematic review of clinical studies on the effect of psychoactive cannabinoids in psychiatric conditions in Alzheimer dementia. Am J Ther. 2020;27:e249–e269.
Coman L, Păunescu H, Catană R, et al. Alzheimer's disease – estrogens and selective estrogen receptor modulators, friends or foes? Acta Endocrinol (Buchar). 2017;13:77–83.
Zanos P, Nelson ME, Highland JN, et al. A negative allosteric modulator for α5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice. eNeuro. 2017;4:ENEURO.0285-16.2017.
Gurrell R, Iredale P, Evrard A, et al. Pronounced antiseizure activity of the subtype‐selective GABAA positive allosteric modulator darigabat in a mouse model of drug‐resistant focal epilepsy. CNS Neurosci Ther. 2022;28:1875–1882.
Gurrell R, Gorman D, Whitlock M, et al. Photosensitive epilepsy: robust clinical efficacy of a selective GABA potentiator. Neurology. 2019;92:e1786–e1795.
Gurrell R, Chang I, Dandurand A, et al. Phase 1 trial of darigabat for the reduction of acute psychological and physiological panic and fear symptoms following CO2 inhalation in healthy participants (S8.005). Neurology. 2023;100:1752.